Leukemia Clinical Trials in Nashville

Showing 1281-1300 of 1,521 trials

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

NCT00609804

This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.

Non-Small Cell Lung Cancer

SCRI Development Innovations, LLC53 participantsStarted Mar 2008

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Marietta, Georgia, United States +13 more locations

COMPLETED< 1 mile

Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

NCT01522833

With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.

Non Small Cell Lung Cancer

SCRI Development Innovations, LLC27 participantsStarted Oct 2012

Nashville, Tennessee, United States

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

Leukemia Trials in Other Cities

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Feasibility Testing of the Quality-monitoring Tool, Qdact, for the Palliative Care Research Cooperative

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Blood and Marrow Transplant Clinical Research Network

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

Imexon for Relapsed Follicular and Aggressive Lymphomas

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Other Conditions in Nashville